STABILITY Investigators Selected Research

darapladib

12/2021	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.
1/2020	Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
1/2020	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.
1/2019	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
10/2017	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
10/2017	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial.
8/2017	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease.
1/2017	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
7/2016	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease.
1/2016	Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

STABILITY Investigators Research Topics

Disease

11	Coronary Disease (Coronary Heart Disease) 01/2020 - 05/2014
8	Myocardial Infarction 12/2021 - 05/2014
8	Atherosclerotic Plaque (Atheroma) 12/2021 - 05/2014
8	Stroke (Strokes) 12/2021 - 05/2014
4	Heart Failure 01/2020 - 01/2016
3	Inflammation (Inflammations) 12/2021 - 10/2017
2	Dyslipidemias (Dyslipidemia) 01/2020 - 10/2017
2	Neoplasms (Cancer) 10/2017 - 01/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2021
1	Chronic Renal Insufficiency 12/2021
1	Necrosis 01/2020
1	Atherosclerosis 10/2017
1	Tooth Loss 10/2017
1	Sudden Death 01/2017
1	Coronary Artery Disease (Coronary Atherosclerosis) 07/2016

Drug/Important Bio-Agent (IBA)

11	darapladibIBA 12/2021 - 05/2014
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2016
4	omega-Chloroacetophenone (Mace)IBA 12/2021 - 07/2016
4	Interleukin-6 (Interleukin 6)IBA 12/2021 - 10/2017
4	C-Reactive ProteinIBA 01/2020 - 01/2017
4	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 01/2020 - 05/2014
3	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2020 - 01/2017
2	LDL CholesterolIBA 01/2020 - 01/2020
2	Growth Differentiation Factor 15IBA 10/2017 - 01/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2020
1	CeramidesIBA 01/2020
1	pro-brain natriuretic peptide (1-76)IBA 10/2017
1	Cystatin CIBA 01/2017
1	Troponin T (Troponin T1)IBA 01/2017
1	EnzymesIBA 05/2014

Therapy/Procedure

7	Therapeutics 12/2021 - 07/2016
1	Secondary Prevention 07/2016